Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Erez's HEM TEST notes 2024 > CLL facts > Flashcards

CLL facts Flashcards

1
Q

Unmutated IGHV in CLL %

A

50%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Immunophenotype CLL

A

CD5, CD23, CD19 positive
Dim immunoglobulin, CD20, CD22, CD79b

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

B sym in CLL presentation

A

5-10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

MBL to CLL

A

1-2% a year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Cytogenetic aberrations in CLL

A

del13q, tri 12, del11, del17p

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

del17p % in CLL

A

10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Rai

A

0- lymphocytosis
I- lymphadenopathy
II - Hepato-splenomegaly
III- Anemia (Hb < 11)
IV- Thrombocytopenia (PLT< 100)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Binet

A

A < 3 lymph node areas
B >= 3 lymph nodes
C -Anemia/Thrormbocytopenia (10/100)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

CLL-IPI

A

17p- 4 points
IGHV- Unmutated- 2 points
B2mg- >3.5 2point
Rai > 0 - 1 point
Age > 65 1 point

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

% never needing Tx in CLL

A

30%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

IVIG Tx in CLL

A

Ig < 500
and recurrent infections
given once every 6-8 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Tx for ASx pts in CLL

A

Ibrutinib improved EFS but not OS (87% vs 60%)
Hence not clearly beneficial

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Reasons for disease progression on BTKi in CLL

A

Mutation in BTK binding site (66-80%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Zanu 1st line CLL

A

SEQUOIA trial
vs BR
24 month PFS 85% no OS
p53 also good response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Perioperative instructions for BTKi

A

Discontinue 3-7 days pre surgery
Resume 3-7 days post surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Ibrutinib 1st line Tx in CLL

A

RESONATE-2 (age >65)
iLLUMINATE (age> 65 or comorbities, including 17p)
ECOG1912 (age<70)
All comparing to chemo
No advantage to R addition
60-80% PFS
OS benefit

17
Q

Acala 1st line in CLL

A

ELEVATE-TN
compared to chemo
5 year PFS 70% compared to 20%
adding Obinutuzumab improved PFS to 80% and improves OS!!
Cost of SE

18
Q

Ven 1st line in CLL

A

CLL14
60% 6 year PFS
but only 20% in p53
Improves OS

GLOW - V+I for 15 months (3 months I lead in + 12m V+I)
MDACC for 2 years

19
Q

Ven+ Ibrutinib 1st line in CLL

A

GLOW
3 months of Ibrutinib followed by 12 months of VI
PFS 84%
compared to chloranbucil + O

MDACC
phase II
24 months for all
another 12 months is MR+
95% 5 year PFS
benefit also for p53

Flayer
MRD guided
Double the time to MRD

20
Q

2nd line Tx in CLL

A

Ibrutinib- RESONATE
Acala- ASCEND, ELEVATE-RR
Zanu- ALPINE
vs Ibrutinib
PFS
MURANO
REVENG

21
Q

Richter %

A

10%

22
Q

Richter type %

A

90% DLBCL
10% HL

23
Q

Richter OS

A

DLBCL- median 3-4 mon
HL- 70% 2 year OS

24
Q

Pirtobrutinib in RR CLL

A

BRUIN
Phase II
Most were double class refractory
80% ORR most PR
PFS of 2 years

25
Q

Common mutation of BTK causing resistance to BTKi in CLL

A

C481S
Prirtobrutinib still efective

26
Q

CAR-T in CLL

A

Liso-cell
Not as effective as in DLBCL

27
Q

Favorable risk FISH in CLL

A

del13q

28
Q

CD38 and ZAP70 in CLL

A

correlate with unmutated disease

29
Q

Most common mutation causing resistance to covalent BTKi

A

C481S

30
Q

Pirtobrutunib SE

A

Neutropenia

31
Q

IGHV mutation cutoff in CLL

A

2%

32
Q

IGHV mutation in CLL that has poor prognosis

A

IGHV3-21

33
Q

Administration of BTKi

A

Before bed
After meal
Avoid grapefruit

34
Q

Acala vs Chlorambucil in ND CLL

A

Compared to chlorambucil obino
Acala with PFS not OS
Adding obinotuzumab improves OS

35
Q

Acala vs Ibruitib in RR CLL

A

Non inferior
Less toxicity

36
Q

Zanu vs Ibruitib in RR CLL

A

Better PFS
Less AF
Same HTN
More neutropenia
But not FN

37
Q

Trisomy 12 in CLL

A

Intermediate prognosis
Worse if NOTCH1 present
Can present with strong CD20 and CD79a

Erez's HEM TEST notes 2024 (35 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions